Skip to main content
YIFAN PHARMACEUTICAL CO.,LTD logo

YIFAN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 002019 ISIN · CNE000001K65 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,497 across all filing types
Latest filing 2023-04-14 Investor Presentation
Country CN China
Listing Shenzhen Stock Exchange 002019

About YIFAN PHARMACEUTICAL CO.,LTD

https://www.yifanyy.com

Yifan Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of innovative biologics, specialty small molecules, and traditional Chinese medicine. The company maintains a diverse product portfolio, notably featuring Ryzneuta (efbemalenograstim alfa), a long-acting recombinant human granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia. It is also recognized as a major global supplier of Vitamin B5 (D-calcium pantothenate). Operating with a global perspective, the firm manages integrated R&D and production platforms that adhere to international quality standards. Its core activities span drug discovery, clinical development, and large-scale manufacturing, with a strategic emphasis on therapeutic areas such as oncology, hematology, and dermatology.

Recent filings

Filing Released Lang Actions
关于举行2022年度业绩说明会的通知
Investor Presentation Classification · 85% confidence The document is a notice about holding a 2022 annual performance briefing meeting (业绩说明会) by the company 亿帆医药股份有限公司. It mentions the date and format of the meeting, the personnel attending, and invites investors to participate and submit questions. It references that the 2022 Annual Report has already been disclosed on April 15, 2023, but this document itself is not the report or the transcript of the meeting. It is an announcement about the upcoming performance explanation meeting, which is typically an investor presentation or briefing. The document length is short (1239 characters), and it does not contain financial data or detailed analysis, only the meeting notice and arrangements. Therefore, it fits best as an Investor Presentation (IP) type document, as it is about a detailed presentation for investors focusing on financials, strategy, and market position, even though the actual presentation content is not included here, the notice is about the event where such presentation will be made. It is not a Report Publication Announcement (RPA) because it is not announcing the release of a report but the holding of a meeting. It is not a Call Transcript (CT) because it is not a transcript. Hence, the best classification is Investor Presentation (IP).
2023-04-14 Chinese
独立董事对担保等事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on various matters discussed at the company's eighth board of directors' fifth meeting. It includes opinions on external guarantees, related party transactions, profit distribution proposals for 2022, internal control self-evaluation report, reappointment of the audit firm, use of idle raised funds for cash management, entrusted financial management, foreign exchange hedging, related party guarantees, and asset impairment provisions. The document references the 2022 fiscal year and the company's audited financial results but does not itself contain full financial statements or detailed financial data. It is a formal opinion report by independent directors on board meeting matters, not a full annual report or audit report. The document length is under 5,000 characters, and it is a formal opinion statement rather than a report or announcement of a report. Therefore, it fits best under Board/Management Information (MANG), as it relates to board meeting opinions and governance matters rather than a full financial report or announcement.
2023-04-14 Chinese
内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2022年度内部控制自我评价报告" which translates to "2022 Annual Internal Control Self-Evaluation Report". It is a detailed report on the company's internal control evaluation for the fiscal year ending December 31, 2022. The content includes evaluation of internal control effectiveness, risk assessment, control activities, information and communication, and internal supervision. It also discusses the absence of major internal control deficiencies related to financial reporting and non-financial reporting. The document is comprehensive and contains substantive information about internal controls rather than just an announcement or summary. It is not an annual report (10-K) but a specialized internal control report. This type of document aligns with an Audit Report / Information (AR) category, which includes standalone audit reports and internal control evaluations. The document is not a certification letter, announcement, or a brief summary, so it does not fit into RNS or RPA. Therefore, the best classification is AR with high confidence. FY 2022
2023-04-14 Chinese
关于使用自有资金进行委托理财的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by a company regarding the use of its own funds for entrusted financial management, specifically investing in low-risk short-term financial products. It details the investment purpose, amount, risk analysis, control measures, and independent director opinions. The document is an announcement of a corporate financing activity related to the company's capital management and investment strategy, but it is not a financial report, earnings release, or regulatory filing. It does not contain financial statements or detailed financial data but rather informs shareholders and the public about the company's financing/investment decision. Therefore, it fits best under Capital/Financing Update (CAP). The document length is 2280 characters, which is consistent with an announcement rather than a full report.
2023-04-14 Chinese
内部控制基本制度（2023年4月修订）
Governance Information Classification · 95% confidence The document is titled '内部控制基本制度' (Internal Control Basic System) and is issued by Yifan Pharmaceutical Co., Ltd. It is a detailed internal control policy document covering governance structure, risk assessment, control activities, information and communication, internal supervision, and specific risk controls. It references compliance with laws, regulations, and stock exchange guidelines, and includes roles and responsibilities of board, audit committee, management, and employees. The document is a comprehensive internal control framework and policy, not a financial report, earnings release, or announcement. It does not contain financial statements or results but focuses on governance and internal control systems. This fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2023-04-14 Chinese
关于开展外汇套期保值业务的可行性分析报告
Regulatory Filings Classification · 95% confidence The document is a detailed report analyzing the feasibility of conducting foreign exchange hedging business by the company. It discusses the background, necessity, business overview, risk analysis, risk management measures, and concludes on the feasibility of the hedging activities. There are no financial statements or quarterly/yearly financial results presented. The document is not an announcement of a report publication but a substantive internal analysis report. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a specialized report on risk management and hedging strategy, which aligns best with a Regulatory Filings (RNS) category as it is a regulatory disclosure about risk management activities and hedging business feasibility, not a financial report or announcement of voting, capital changes, or management changes.
2023-04-14 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.